Description du projet
Améliorer l’efficacité des nanogels inhalables pour traiter le cancer du poumon
Les nanogels sont des systèmes prometteurs de transport de médicaments capables d’administrer des produits thérapeutiques dans des cellules ciblées du corps. Ils ont récemment fait l’objet d’applications polyvalentes dans le traitement de troubles et de maladies, y compris le cancer. Bien que l’administration pulmonaire de produits thérapeutiques par le biais de nanogels inhalables soit considérée comme avantageuse pour le traitement du cancer du poumon, plusieurs défis doivent être relevés en vue d’une utilisation plus large. Le projet PuDeRegels, financé par l’UE, tentera d’améliorer l’efficacité des nanogels afin qu’ils puissent administrer de manière précise et sûre des médicaments anticancéreux dans les poumons par le biais du système respiratoire. En combinant son expertise dans les domaines de la science des polymères et de la biologie chimique, PuDeRegels entend surmonter les défis liés à l’encapsulation du médicament anticancéreux, à l’administration ciblée, à la libération du médicament, à la biocompatibilité et à l’évitement des macrophages.
Objectif
In this project, I will investigate and develop nanogels incorporated into microgels containing encapsulated anticancer drugs. These nanogels will be delivered via the respiratory system to the lung, selectively swell and deliberate the therapeutic. Importance will be given to targeting moieties, stealth moieties, and biocompatibility. The delivery of drugs for lung cancer is limited but is under investigation and on the rise of inquiry. Some of the challenges this type of technology faces are the efficient encapsulation of the bioactive compound inside a nanocarrier, the targeted delivery, the release of the drug, the biocompatibility with the lung, and the avoidance of the macrophages. New methodologies for better delivery of therapeutics are of great importance at the National and International levels. New materials and technologies are emerging every year. The delivery of therapeutics for lung cancer is based mainly on intravenous therapies. Another way of introducing drugs into the area of importance in the lung could be pulmonary drug delivery as a good alternative. Pulmonary delivery is not a new technology but is strictly limited to specific conditions/illnesses. The research capitalizes on the existing strengths of the experienced researcher (ER) in polymer science and the expertise of the host institute in chemical biology in health, drug research, and biotechnology. It will lead to several publications in high-impact factor journals, transfer of knowledge and expertise that could be capitalized at an industrial level, thus contributing to the research output, distinctness, and economy of Europe. Overall, the fellowship will allow the ER to reintegrate into a long-term academic position after many years of fruitful research career in the academic sector in Spain. After this project, the ER will obtain new knowledge and training that will help him to establish a solid point for a better opportunity both in Academy and in Industry.
Champ scientifique
Programme(s)
Régime de financement
HORIZON-AG-UN - HORIZON Unit GrantCoordinateur
11635 Athina
Grèce